FDA approves Enspryng for neuromyelitis optica spectrum disorder

The FDA has approved Enspryng for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, according to a Genentech press release.
Enspryng (satralizumab-mwge) is the first subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) that can be administered by the patient or caregiver at home after receiving training from a health care provider. The treatment is given every 4 weeks after the initial loading dose.
It is designed to target and inhibit interleukin-6 receptor activity. FDA approval was based on results from two randomized, controlled

Full Story →

FDA approves Enspryng for neuromyelitis optica spectrum disorder

The FDA has approved Enspryng for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, according to a Genentech press release.
Enspryng (satralizumab-mwge) is the first subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) that can be administered by the patient or caregiver at home after receiving training from a health care provider. The treatment is given every 4 weeks after the initial loading dose.
It is designed to target and inhibit interleukin-6 receptor activity. FDA approval was based on results from two randomized, controlled

Full Story →